ASTCT Pharmacy SIG Journal Club - June 2023

The June 2023 Pharmacy SIG Journal Club will air on Wednesday, June 7 from 2-3 PM CDT. In the June Journal Club session, Drs. Chen and Scott will present on two articles related to use of (a) defibrotide for prophylaxis of sinusoidal obstruction syndrome and (b) allogeneic transplant in newly diagnosed patients with AML following venetoclax/azacytidine or intensive induction. This session is intended for pharmacists and other members of the health care team who are involved in managing patients undergoing allogeneic stem cell transplant. 

Presenters & Articles

Teaghan Chen, PharmD

PGY-2 Pharmacy Resident

Children’s Hospital Colorado

Defibrotide plus best standard of care compared with best standard of care alone for the prevention of sinusoidal obstruction syndrome (harmony): a randomised, multicentre, phase 3 trial

Campbell Scott, PharmD

PGY-2 Pharmacy Resident

University of Georgia

Outcomes Are Similar After Allogeneic Hematopoietic Stem Cell Transplant for Newly Diagnosed Acute Myeloid Leukemia Patients who Received Venetoclax + Azacitidine Versus Intensive Chemotherapy

Session Learning Objectives:

Upon completion of the activity, participants should be able to:

1. Describe current standards of care in the prevention of sinusoidal obstruction syndrome
2. Evaluate the safety and efficacy of defibrotide use for the prevention of sinusoidal obstruction syndrome
3. Compare sinusoidal obstruction syndrome outcomes in patients that received defibrotide plus standard of care standard versus care alone
4. Summarize the role of venetoclax plus azacitidine in the treatment of patients with newly diagnosed acute myeloid leukemia
5. Compare post-allogeneic hematopoietic stem cell transplant outcomes between patients who received initial induction with venetoclax plus azacitidine or an intensive chemotherapy regimen